^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Small Lymphocytic Lymphoma |
| Drug: | Zydelig (idelalisib) (PI3Kδ inhibitor) |
| Regimen: | BR (bendamustine + Rituxan (rituximab)) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
02/19/2021
Excerpt:
BR ± idelalisib or ibrutinib is included as an option for relapsed/refractory therapy, regardless of patient's age or comorbidities.
